2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
The Correlation Between Donor Specific Antibodies and Heart Transplant Rejection
The presence of donor specific HLA antibodies (DSA) has been shown to be detrimental to heart transplant (HTx) survival. Virtual crossmatching (VXM) offers a rapid…2015 American Transplant Congress
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
1CareDx, Inc, Brisbane, CA; 2Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a potential biomarker of acute cellular rejection (ACR) in organ transplant recipients. dd-cfDNA levels in longitudinal plasma samples from…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…2015 American Transplant Congress
Elevated ST2 Levels Are Associated With Increased Risk of Antibody Mediated Rejection in Heart Transplant Recipients
Objective: Serum ST2, a member of the interleukin (IL) 1 receptor family, is a novel biomarker that reflects cardiac remodeling and fibrosis and is associated…2015 American Transplant Congress
Longitudinal Multi-Omic Profiling of Genes and Pathways Underlying Cardiac Allograft Rejection
Our ability to treat cardiac allograft rejection in both acute and chronic states is typically limited by poor existing biomarkers to predict the occurrence of…2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…2015 American Transplant Congress
Risk of HLA Antibody Sensitization in Pediatric Heart Failure Patients Pre/Post Berlin VAD Procedure and Pre/Post Heart Transplantation
Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX.
The Berlin Heart Excor Ventricular Assist Device (Berlin VAD) was designed for use in children with heart failure. The Berlin VAD has allowed for successful…2015 American Transplant Congress
Influence of POR*28 Genotype on Tacrolimus Disposition in Heart Transplant Recipients
Polymorphisms in P450 oxidoreductase (POR) have been shown to modulate CYP3A activity and alter the pharmacokinetics of CYP3A substrates, such as tacrolimus (TAC). The objective…
American Transplant Congress abstracts